Evidence map›Paper›PMID 19535627›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2009

Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody.

Hameeda Sultana, Harald G Foellmer, Girish Neelakanta, Theodore Oliphant, Michael Engle, Michel Ledizet, Manoj N Krishnan, Nathalie Bonafé, Karen G Anthony, Wayne A Marasco and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Arthropod EVs mediate dengue virus transmission through interaction with a tetraspanin domain containing glycoprotein Tsp29Fb.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  8. Article
  9. Article
  10. Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates.The American journal of tropical medicine and hygiene · 2016
    Article
  11. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Hameeda SultanaDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Harald G Foellmer
Girish Neelakanta
Theodore Oliphant
Michael Engle
Michel Ledizet
Manoj N Krishnan
Nathalie Bonafé
Karen G Anthony
Wayne A Marasco
Paul Kaplan
Ruth R Montgomery
Michael S Diamond
Raymond A Koski
Erol Fikrig
CS Diagnostics · DEOffice of Infectious Diseases · USWashington University in St. Louis · USCzech Academy of Sciences, Institute of Microbiology · CZDana-Farber Cancer Institute · USHoward Hughes Medical Institute · USYale University · US

Funding

Immunotherapeutics for Treatment of Flavivirus InfectionU01AI070343 · NIAID · YALE UNIVERSITY · PI FIKRIG, EROL · 2006 to 2010
$6.6M
Monoclonal Antibody Therapy for West Nile VirusU01AI061373 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S · 2005 to 2009
$5.1M
Toll-like receptor responses to West Nile virusR01AI055749 · NIAID · YALE UNIVERSITY · PI FIKRIG, EROL · 2003 to 2007
$1.4M
IMMUNE FUNCTION AND BIODEFENSE IN CHILDREN. ELDERLY AND IMMUNOCOMPROMI-266050031N01AI050031 · NIAID · EMORY UNIVERSITY · PI LARSEN, CHRISTOPHER · 2006 to 2006
–
NIAID NIH HHS AI061373NIAID NIH HHS AI 070343NIAID NIH HHS AI 50031NIAID NIH HHS N01 AI050031NIAID NIH HHS R01 AI055749NIAID NIH HHS U01 AI061373NIAID NIH HHS U01 AI070343
6 · The paper itself

Abstract

West Nile virus is an emerging pathogen that can cause fatal neurological disease. A recombinant human mAb, mAb11, has been described as a candidate for the prevention and treatment of West Nile disease. Using a yeast surface display epitope mapping assay and neutralization escape mutant, we show that mAb11 recognizes the fusion loop, at the distal end of domain II of the West Nile virus envelope protein. Ab mAb11 cross-reacts with all four dengue viruses and provides protection against dengue (serotypes 2 and 4) viruses. In contrast to the parental West Nile virus, a neutralization escape variant failed to cause lethal encephalitis (at higher infectious doses) or induce the inflammatory responses associated with blood-brain barrier permeability in mice, suggesting an important role for the fusion loop in viral pathogenesis. Our data demonstrate that an intact West Nile virus fusion loop is critical for virulence, and that human mAb11 targeting this region is efficacious against West Nile virus infection. These experiments define the molecular determinant on the envelope protein recognized by mAb11 and demonstrate the importance of this region in causing West Nile encephalitis.

Indexed as

Binding Sites, AntibodyAnimalsAntibodies, MonoclonalCell LineCross ReactionsDengue VirusFemaleHumansMiceMice, Inbred BALB CMice, Inbred C57BLPeptidesProtein Structure, TertiaryRecombinant Fusion ProteinsViral Envelope ProteinsViral Fusion ProteinsAntibodies, MonoclonalPeptidesRecombinant Fusion ProteinsViral Envelope ProteinsViral Fusion Proteins

Identifiers

PMID19535627
PMCPMC3690769
OpenAlexW1892505043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.